How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,985 results for

E/M Established Outpatient Visit


Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. British Association of Dermatologists guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in children and young people

Management of infection (causative and secondary) Psychological interventions The GDG also established a set of outcome measures of importance to patients (treatment), which were agreed by the patient representatives, and ranked according to the GRADE methodology; data on these outcome measures were extracted from the included studies (Table and Appendices C, D and E; see Supporting Information). Table 2. Important outcome measures for Stevens–Johnson syndrome/toxic epidermal necrolysis in children (...) term Search term The full text of this article hosted at is unavailable due to technical difficulties. Navigation Bar Menu Guidelines Free Access British Association of Dermatologists' guidelines for the management of Stevens–Johnson syndrome/toxic epidermal necrolysis in children and young people, 2018 Corresponding Author E-mail address: E-mail address: Oxford University Hospitals NHS Foundation Trust, Old Road, Headington, Oxford, OX3 7LE U.K Correspondence Tess McPherson. E‐mails

2019 British Association of Dermatologists

142. Substance use disorders in pregnancy: clinical, ethical, and research imperatives of the opioid epidemic

, ability to test for multiple substances, and well-established validity. x 36 Wolff, K., Farrell, M., Marsden, J. et al. A review of biological indicators of illicit drug use, practical considerations and clinical usefulness. Addiction . 1999 ; 94 : 1279–1298 However, biologic tests do not distinguish between occasional and regular use. x 20 US Preventative Services Task Force. Screening for illicit drug use: US Preventive Services Task Force Final Recommendation Statement. Available at: . Accessed (...) Ecker , MD , x Alfred Abuhamad , MD , x Washington Hill , MD , x Jennifer Bailit , MD , x Brian T. Bateman , MD , x Vincenzo Berghella , MD , x Tiffany Blake-Lamb , MD , x Constance Guille , MD , x Ruth Landau , MD , x Howard Minkoff , MD , x Malavika Prabhu , MD , x Emily Rosenthal , MD , x Mishka Terplan , MD , x Tricia E. Wright , MD , x Kimberly A. Yonkers , MD Society for Maternal-Fetal Medicine, Washington, DC DOI: | Publication History Published online: March 27, 2019 Expand all Collapse all

2019 Society for Maternal-Fetal Medicine

143. Management of Stroke Rehabilitation

. About this Clinical Practice Guideline 7 A. Methods 7 a. Grading Recommendations 8 b. Reconciling 2010 Clinical Practice Guideline Recommendations 10 c. Peer Review Process 11 B. Summary of Patient Focus Group Methods and Findings 11 C. Conflicts of Interest 12 D. Scope of this Clinical Practice Guideline 13 E. Highlighted Features of this Clinical Practice Guideline 13 F. Patient-centered Care 13 G. Shared Decision Making 14 H. Co-occurring Conditions 14 I. Implementation 14 IV. Guideline Work (...) Group 15 V. Algorithm 17 A. Module A: Rehabilitation Disposition of the Inpatient with Stroke 18 B. Module B: Outpatient/Community-Based Rehabilitation 19 VI. Recommendations 23 A. Approach and Timing 27 B. Motor Therapy 30 a. Upper and Lower Limbs Rehabilitation 30 b. Technology-Assisted Physical Rehabilitation 37 c. Pharmacological Treatment in Motor Therapy 45 C. Dysphagia Therapy 48 D. Cognitive, Speech, and Sensory Therapy 55 a. Cognitive Therapy 55 b. Speech Therapy 56 c. Spatial Neglect

2019 VA/DoD Clinical Practice Guidelines

144. Assessment and Management of Patients at Risk for Suicide

Affairs Populations 8 C. Identifying Suicide Risk in VA and DoD Populations 9 III. About this Clinical Practice Guideline 10 A. Methods 11 a. Grading Recommendations 12 b. Reconciling 2013 Clinical Practice Guideline Recommendations 13 c. Peer Review Process 14 B. Summary of Patient Focus Group Methods and Findings 14 C. Conflicts of Interest 16 D. Scope of this Clinical Practice Guideline 16 E. Highlighted Features of this Clinical Practice Guideline 17 F. Patient-centered Care 17 G. Shared Decision (...) VA/DoD Clinical Practice Guideline for the Assessment and Management of Patients at Risk for Suicide May 2019 Page 4 of 142 C. Other Management Modalities 50 a. Population & Community-based Interventions 50 D. Knowledge Gaps and Recommended Research 54 a. Screening for Suicide Risk 54 b. Evaluation, Determining Level of Risk, and Relationship to Treatment 54 c. Risk and Protective Factors 54 d. Non-pharmacologic Interventions 55 e. Pharmacologic Interventions 55 f. Post-acute Care Approaches 56 g

2019 VA/DoD Clinical Practice Guidelines

145. Pre-emptive compared with empirical antifungal strategies for invasive Aspergillus infection

4.0 Licence. This allows for the copy and redistribution of this document as long as Healthcare Improvement Scotland is fully acknowledged and given credit. The material must not be remixed, transformed or built upon in any way. To view a copy of this licence, visit nd/4.0/ SHTG Evidence Synthesis | 20 References 1. Fung M, Kim J, Marty FM, Schwarzinger M, Koo S. Meta-analysis and cost comparison of empirical versus (...) . 2016;8:275-85. 23. Barnes R, Earnshaw S, Herbrecht R, Morrissey O, Slavin M, Bow E, et al. Economic comparison of an empirical versus diagnostic-driven strategy for treating invasive fungal disease in immunocompromised atients. Clin Ther. 2015;37(6):1317-28. 24. Macesic N, Morrissey CO, Liew D, Bohensky MA, Chen SC, Gilroy NM, et al. Is a biomarker- based diagnostic strategy for invasive aspergillosis cost effective in high-risk haematology patients? Med Mycol. 2017;55(7):705-12.

2019 SHTG Advice Statements

146. HTA of C-reactive protein point-of-care testing to guide antibiotic prescribing

Information and Quality Authority iii About the Health Information and Quality Authority (HIQA) The Health Information and Quality Authority (HIQA) is an independent statutory authority established to promote safety and quality in the provision of health and social care services for the benefit of the health and welfare of the public. HIQA’s mandate to date extends across a wide range of public, private and voluntary sector services. Reporting to the Minister for Health and engaging with the Minister (...) - of-care test with evidence for patients with symptoms of acute respiratory tract infection applicable to the primary care setting. The HTA aimed to establish the clinical and cost-effectiveness of CRP POCT. The HTA also examined the organisational implications of the potential introduction of the technology in primary care. The key findings of this HTA, which informed HIQA’s advice, are: ? Respiratory tract infections (RTIs) are the most frequent infections encountered in primary care, accounting

2019 Health Information and Quality Authority

147. The economic evaluation of early intervention with Anti-Tumor Necrosis Factor-? treatments in pediatric Crohn's disease

Physician, Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, Canada Anne M. Griffiths, MD Staff Physician, Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, Canada Shinya Ito, MD Head, Division of Clinical Pharmacology & Toxicology, The Hospital for Sick Children, Toronto, Canada Professor, Faculty of Medicine, The University of Toronto, Toronto, Canada Wendy J. Ungar, MSc, PhD Senior Scientist, Child Health Evaluative Sciences (...) Overview of Methods and Study Design 27 2.2 The Pediatric Crohn’s Disease Cohort 29 2.2.1 The RISK-PROKIIDS Study Data 29 Inclusion Criteria 30 2.2.2 Data Extraction and Patient Characteristics from the RISK-PROKIIDS Study 32 Assigning Visit Dates 32 Determining Patient Health State 34 The Weighted Pediatric Crohn’s Disease Activity Index and the Physician Global Assessment 35 Treatment Determination 38 Extracting Patient Characteristics and Covariate

2019 SickKids Reports

148. A cost-utility analysis of biosimilar infliximab compared to reference infliximab in adult switch patients with Crohn’s disease: A Canadian analysis

Policy, Management and Evaluation, University of Toronto, Toronto, Canada John Marshall, MD, MSc Professor and Director of the Division of Gastroenterology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada Myla E. Moretti, MSc, PhD Senior Research Associate, Ontario Child Health Support Unit and the Clinical Trials Unit, The Hospital for Sick Children, Toronto, Ontario, Canada Assistant Professor, Institute for Health Policy, Management and Evaluation, University of Toronto (...) 17 - Administration Costs 77 Table 18 – Immunosuppressive & Steroid Treatment Cost 78 Table 19 - ICD-10 Codes for Crohn's Disease Costs (OCCI 2015/16) 78 Table 20 - Average Surgical Cost Resection & Length of Stay 79 10 Table 21 - Average Surgical Length of Stay 79 Table 22 - Surgical Procedure Fee 79 Table 23 - Surgical Consultations 80 Table 24 - Post Surgical General Surgery Fees 80 Table 25- Ontario Schedule of Benefits: Surgical and Physician Visit Costs 80 Table 26 - Physician Visits 81

2019 SickKids Reports

149. Asymptomatic Bacteriuria

: 2019 Update by the Infectious Diseases Society of America a Lindsay E. Nicolle, 1 Kalpana Gupta, 2 Suzanne F. Bradley, 3 Richard Colgan, 4 Gregory P . DeMuri, 5 Dimitri Drekonja, 6 Linda O. Eckert, 7 Suzanne E. Geerlings, 8 Béla Köves, 9 Thomas M. Hooton, 10 Manisha Juthani-Mehta, 11 Shandra L. Knight, 12 Sanjay Saint, 13 Anthony J. Schaeffer, 14 Barbara Trautner, 15 Bjorn Wullt, 16 and Reed Siemieniuk 17 1 Department of Internal Medicine, School of Medicine, Rady Faculty of Health Sciences (...) transplant recipients followed for 1 year after transplant, with urine routinely screened with culture every 3 days for the first 2 weeks, weekly to 1 month, and at each outpatient follow-up visit, reported that 53% of subjects had at least 1 positive urine culture; 53% of the bacteriuric epi- sodes were considered asymptomatic, and 40% of patients had at least 1 episode of ASB [112]. More than one-half of positive cultures were identified in the first month after transplantation, when screening was most

2019 Infectious Diseases Society of America

150. Urological Infections

, 2002. 287: 2701. 105. Bradbury, S.M. Collection of urine specimens in general practice: to clean or not to clean? J R Coll Gen Pract, 1988. 38: 363. 106. Lifshitz, E., et al. Outpatient urine culture: does collection technique matter? Arch Intern Med, 2000. 160: 2537. 107. Fihn, S.D. Clinical practice. Acute uncomplicated urinary tract infection in women. N Engl J Med, 2003. 349: 259. 108. Foxman, B., et al. Epidemiology of urinary tract infections: transmission and risk factors, incidence (...) , Center for Drug Evaluation and Research (CDER). Complicated Urinary Tract Infections: Developing Drugs for Treatment Guidance for Industry 2018. 11. Johansen, T.E., et al. Critical review of current definitions of urinary tract infections and proposal of an EAU/ESIU classification system. Int J Antimicrob Agents, 2011. 38 Suppl: 64. 12. Singer, M., et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA, 2016. 315: 801. 13. Bell, B.G., et al. A systematic

2019 European Association of Urology

151. BSG consensus guidelines on the management of inflammatory bowel disease in adults

:// Matthew J. Brookes: Richard Hansen: A. Barney Hawthorne: Contributors (IBD guidelines eDelphi consensus group) Ian Arnott, Kevin J. Barrett, R. Mark Beattie, Stuart Bloom, Keith Bodger, Richard R. Brady, Matthew J. Brookes, Steven R. Brown, Jeffrey R. Butterworth, Christopher R. Calvert, Rachel Campbell, Tom Creed, Nicholas M. Croft, Fraser Cummings, R. Justin (...) Davies, David Devadason, Anjan Dhar, Chris Dipper, Julie Duncan, Malcolm Dunlop, Dharmaraj Durai, Martyn D. Evans, Omar Faiz, Nicola S. Fearnhead, Alexander C. Ford, Aileen Fraser, Vikki Garrick, Daniel R. Gaya, James Goodhand, Nigel Hall, Richard Hansen, Marcus Harbord, A. Barney Hawthorne, Bu'Hussain Hayee, Sarah Hearnshaw, Paul Henderson, Philip Hendy, Tariq Iqbal, Paul D. Johnston, Nicholas A. Kennedy, Christopher A. Lamb, Jimmy K. Limdi, James O. Lindsay, Alan J. Lobo, Miranda Lomer, Richard E

2019 British Society of Gastroenterology

152. Health technology assessment of a PrEP programme for populations at substantial risk of sexual acquisition of HIV

authority established to promote safety and quality in the provision of health and social care services for the benefit of the health and welfare of the public. HIQA’s mandate to date extends across a wide range of public, private and voluntary sector services. Reporting to the Minister for Health and engaging with the Minister for Children and Youth Affairs, HIQA has responsibility for the following: ? Setting standards for health and social care services — Developing person-centred standards (...) to identify potentially eligible studies. Full text articles were obtained for all citations identified as potentially relevant for inclusion. Both reviewers independently inspected these to establish the relevance of the articles according to the pre-specified criteria. Studies were reviewed for relevance based on study design, types of participants, interventions and outcome measures (see Table 4.1). 4.2.4 Data extraction and management Data were independently extracted using an agreed data extraction

2019 Health Information and Quality Authority

153. Guidance on the clinical management of anxiety disorders, specifically focusing on diagnosis and treatment strategies

time, alternative causes of anxiety such as mood or substance use disorders, physical illness or its treatment should be considered (Lampe, 2015; McEvoy et al., 2011). Anxiety disorders are associated with high levels of dis- tress, disability and service use (Slade et al., 2009b), yet only a minority of people with anxiety disorders get ade- quate treatment (Harris et al., 2015). Fewer than half seek treatment by visiting a health professional. Those who do, commonly attend primary care and only (...) management of anxiety disorders also involves consideration of issues for people in various age groups, sociocultural diversity, issues for indigenous cultures, and important comorbidities. First published in the Australian and New Zealand Journal of Psychiatry 2018, Vol. 52(12) 1109-1172.1118 ANZJP Articles Structured clinical interviews. There are four well-established diagnostic interviews that generate a reliable and valid diagnosis: • • Structured Clinical Interview for Axis 1 DSM-IV Disorders

2018 Royal Australian and New Zealand College of Psychiatrists

154. Home-Based Cardiac Rehabilitation: Scientific Statement

services (e.g., medications, outpatient care, inpatient care), 2 reports found no signi?cant difference in use between HBCR and CBCR (41,70), and 1 study reported fewer medical visits and hospitalizations with HBCR (53). Quality-adjusted life-years were reported in 2 studies, and both found no signi?cant difference in quality-adjusted life-years be- tweenHBCRandCBCR(41,70).OnestudyfromtheUnited Statesincludedlimitedcostdataandsuggestedthatcosts may be lower for HBCR compared with CBCR (35). Risk (...) are generally not covered by third-party payers in the United States. One exception is the MULTIFIT home-based pro- gram implemented at Kaiser Permanente Northern Cali- fornia (77). This nurse-based case management system starts during hospitalization for acute MI or revasculari- zation and is followed over the subsequent 6 months by up to 12 nurse-initiated telephone contacts, up to 4 outpatient visits with a nurse case manager, and computer-generated progress reports based on patient

2019 American College of Cardiology

155. Recovery schools for improving behavioral and academic outcomes among students in recovery from substance use disorders: a systematic review

Recovery schools for improving behavioral and academic outcomes among students in recovery from substance use disorders: a systematic review A Campbell Systematic Review 2018:9 Education Coordinating Group Emily A. Hennessy, Emily E. Tanner-Smith, Andrew J. Finch, Nila Sathe, Shannon Kugley Recovery schools for improving behavioral and academic outcomes among students in recovery from substance use disorders: a systematic review Published: October 2018 Search executed: September 2018The (...) Campbell Library comprises: • Systematic reviews (titles, protocols and reviews) • Policies and Guidelines Series • Methods Series Go to the library to download these resources, at: Better evidence for a better world Colophon Title Recovery schools for improving behavioral and academic outcomes among students in recovery from substance use disorders: a systematic review Authors 1 Emily A. Hennessy 2 Emily E. Tanner-Smith 3 Andrew J. Finch 4 Nila Sathe 5 Shannon

2018 Campbell Collaboration

156. Guidelines for the Economic Evaluation of Health Technologies in Ireland

) is an independent authority established to drive high-quality and safe care for people using our health and social care services in Ireland. HIQA’s role is to develop standards, inspect and review health and social care services and support informed decisions on how services are delivered. HIQA aims to safeguard people and improve the safety and quality of health and social care services across its full range of functions. HIQA’s mandate to date extends across a specified range of public, private and voluntary (...) at SAG meetings as appropriate ? be prepared to occasionally provide expert advice on relevant issues outside of SAG meetings, as requested ? support HIQA in the generation of guidelines to establish quality standards for the conduct of HTA in Ireland ? support HIQA in the development of methodologies for effective HTA in Ireland ? advise HIQA on its proposed HTA Guidelines Work Plan and on priorities as required ? support HIQA in achieving its objectives outlined in the HTA Guidelines Work Plan

2019 Health Information and Quality Authority

157. Peramivir (Alpivab) - Influenza, Human

. There are no licensed intravenous presentations of neuraminidase inhibitors in the EU although these may be available for compassionate use in severely ill patients, in whom their efficacy has not been established. Otherwise, treatment for severe influenza is supportive and may involve the need for assisted ventilation, circulatory support and antibacterial agents to treat or prevent secondary bacterial infections, such as staphylococcal pneumonia. In some countries amantadine and rimantadine (the adamantanes (...) 7 days 200 d C0 e 913140 308616 19.8x 3.1x IV continuous Infusion 2 weeks 1152 69277 h NC 1.51x NC IV bolus 4 weeks 120 g 675125 383234 14.8x 3.8x IV continuous Infusion 30-31 days 1440 NC 1975000 14.8x 3.8x Rabbit IV bolus 7 day 100 C0 e 159000 219000 3.4x 2.1x IV bolus 7 day 100 C0 e 454159 337718 9.9x 3.3x Monkey IM 2 weeks 54 197875 287193 4.3x 2.8x 52 weeks 54 206917 239176 4.5x 2.3x IV bolus 2 weeks 45 375000 249000 8.2x 2.4x 4 weeks 90 485000 541580 10.6x 2.5x IV continuous Infusion 30-31

2018 European Medicines Agency - EPARs

158. Guideline regarding treatment of haemorrhoids

for these conditions should be applied (expert opinion, upgraded by guideline development group). 19 5. Basic treatment for haemorrhoids 5.1 Introduction When a patient visits the outpatient clinic with ano-rectal symptoms which may include bleeding, pain, prolapse, itching and/or soiling and the healthcare provider makes a diagnosis of haemorrhoidal disease, the first management step will consist of basic treatment. Basic treatments could be used for symptom relief and to prevent prolapse and includes toilet (...) University Medical Centre +, 6202 AZ Maastricht, the Netherlands 2 Index Index 2 1. Recommendations 6 1.1 Evaluation: symptoms, diagnosis and classification 6 1.2 Basic treatment 6 1.3 Outpatient procedures 7 1.4 Surgical interventions 7 1.5 Special situations 7 1.6 Other surgical techniques 8 2. Introduction 10 3. Methodology 11 4. Evaluation: symptoms, diagnosis and classification 14 4.1 Definition and pathophysiology 14 4.2 Review questions 15 4.3 Diagnosis 16 4.4 Classification 17 4.5 Conclusion 17

2019 Palliative Care Evidence Review Service (PaCERS)

159. Pharmacologic and Non-pharmacologic Therapies in Adult Patients with Acute Exacerbation of COPD: A Systematic Review

evidence from clinical studies. For more information about AHRQ EPC systematic reviews, see AHRQ expects that these systematic reviews will be helpful to health plans, providers, purchasers, government programs, and the healthcare system as a whole. Transparency and stakeholder input are essential to the Effective Health Care Program. Please visit the Web site ( to see draft research questions and reports or to join (...) an e- mail list to learn about new program products and opportunities for input. If you have comments on this systematic review, they may be sent by mail to the Task Order Officer named below at: Agency for Healthcare Research and Quality, 5600 Fishers Lane, Rockville, MD 20857, or by email to Gopal Khanna, M.B.A. Arlene Bierman, M.D., M.S. Director Director Agency for Healthcare Research and Quality Center for Evidence and Practice Improvement Agency for Healthcare Research

2019 Effective Health Care Program (AHRQ)

160. National Early Warning Score

and available resources.National Clinical Effectiveness Committee (NCEC) The National Clinical Effectiveness Committee (NCEC) was established as part of the Patient Safety First Initiative in September 2010. The NCECs mission is to provide a framework for national endorsement of clinical guidelines and audit to optimise patient and service user care. The NCEC has a remit to establish and implement processes for the prioritisation and quality assurance of clinical guidelines and clinical audit so (...) and clinical treatment. • Any outpatient/day service patients who attend acute hospitals for an invasive procedure or who receive sedation. • All patients attending an Acute Medical Unit/Acute Medical Assessment Unit/Medical Assessment Unit. The National Clinical Guideline applies to healthcare professionals, doctors, nurses, physiotherapists and other staff involved in the clinical care of patients and managers responsible for the development, implementation, review and audit of deteriorating patient

2019 National Clinical Guidelines (Ireland)

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>